<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442088</url>
  </required_header>
  <id_info>
    <org_study_id>07-17-33</org_study_id>
    <nct_id>NCT03442088</nct_id>
  </id_info>
  <brief_title>Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast</brief_title>
  <official_title>An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label pilot study of the impact of treatment with standard dosing of Otezla
      for 16 weeks on AM-endotype psoriasis patients, identified by elevated (&gt;150% of normal): 1.)
      Intermediate (CD14++CD16+) monocytes, or 2.) circulating monocyte doublets, or 3.)
      circulating monocyte-platelet aggregates (MPA).

      Approximately 25 psoriasis patients with the AM-endotype will be followed during treatment
      over 16 weeks with 4 monthly individual blood draws will be enrolled. 10 untreated healthy
      controls will also be enrolled and will provide two blood draws (baseline and 16 weeks).
      These are needed to maintain quality control of the normal levels of the biomarkers being
      tested. All treated psoriasis subjects will receive apremilast through Week 16
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open label pilot study of the impact of treatment with standard dosing of APM for 16 weeks on AM-endotype psoriasis patients, identified by elevated (&gt;150% of normal): 1.) Intermediate (CD14++CD16+) monocytes % of cells in circulation, or 2.) circulating monocyte doublets % of adherent monocyte-monocyte pairs, or 3.) circulating monocyte-platelet aggregates (MPA) % monocytes adherent to platelets.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure will be to evaluate change in aberrant inflammatory profiles of activated blood monocytes (aberrant-monocyte endotype patients (AM-endotype).</measure>
    <time_frame>16 weeks</time_frame>
    <description>For each subject, we will identify a target biomarker of abnormally elevated monocytes, among 1.) intermediate, or 2.) doublets, or 3.) platelet doubles. Each subject will thus have one identified monocyte biomarker for which relative percent change will be its basis for analysis in the primary outcome measure. We will specifically assess change from baseline to 16 weeks by computing relative percent reduction for each subject being treated. Note for example that a change of 1.5% to 1.2% is (1 - (1.2/1.5))*100% = 20% reduction. The median and other summary statistics of these percent change values will be computed. Wilcoxon's signed rank test will be used to evaluate the null hypothesis of the median percent change being 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum myeloperoxidase, resistin, IL-17 and Tissue Factor in the AM-endotype</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess change in serum myeloperoxidase, resistin, IL-17 and Tissue Factor in the identified patient AM-endotype computing relative percent reduction for each subject being treated and each serum marker. The median and other summary statistics of these percent change values will be computed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate median changes in flow cytometric quantification of monocytes</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess change in quantitation of additional monocyte and neutrophil markers, including CD18/CD11b and NETotic neutrophils by computing relative percent reduction in circulating CD18/CD11b and NETotic neutrophils for each subject being treated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Monocyte Transcriptome Biumarkers</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess change in expression levels of monocyte transcriptome biomarkers using quantitative PCR to measure changes from baseline to 16 weeks in identified monocyte genes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Calculate the percent change in Dermatology Life Quality Index (DLQI) from baseline to 16 weeks in patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent change between Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO</measure>
    <time_frame>16 weeks</time_frame>
    <description>Calculate the percent change Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) from baseline to 16 weeks in patients treated with apremilast 30 mg BID</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Apremilast for Treatment of Psoriasis with the AM-endotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated healthy controls will also be enrolled and will provide two blood draws. These are needed to maintain quality control of the normal levels of the biomarkers being tested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.</description>
    <arm_group_label>Apremilast for Treatment of Psoriasis with the AM-endotype</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, ≥ 18 and &lt; 60 years of age at the time of signing the informed
             consent document.

          2. Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures being conducted.

          3. Able to adhere to the study visit schedule and other protocol requirements.

          4. Patients must exhibit AM-endotype psoriasis patients, identified by elevated (&gt;150% of
             normal) levels of any one of the following criteria: 1.) Intermediate (CD14++CD16+)
             monocytes, or 2.) circulating monocyte doublets, or 3.) circulating monocyte-platelet
             aggregates (MPA).

          5. Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening.

          6. Have moderate to severe plaque psoriasis at Screening and Baseline as defined by a.
             BSA ≥5% b. sPGA ≥3 (moderate to severe)

          7. Must be a candidate for phototherapy and systemic (including Otezla) therapy.

          8. Must be in good health (except for psoriasis) as judged by the Investigator, based on
             medical history and physical examination.

          9. Females of childbearing potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. While on investigational product and for at least 28 days
             after taking the last dose of investigational product, FCBP who engage in activity in
             which conception is possible must use one of the approved contraceptive options
             described below:

        Option 1: Any one of the following highly effective methods: hormonal contraception (oral,
        injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal
        ligation; or partner's vasectomy;

        OR

        Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural
        [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a)
        diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge
        with spermicide.

        The female subject's chosen form of contraception must be effective by the time the female
        subject is randomized into the study (for example, hormonal contraception should be
        initiated at least 28 days before randomization Male subjects (including those who have had
        a vasectomy) who engage in activity in which conception is possible must use barrier
        contraception (male latex condom or non-latex condom NOT made out of natural [animal]
        membrane [for example, polyurethane]) while on investigational product and for at least 28
        days after the last dose of investigational product.

        Exclusion Criteria:

          -  1. Other than psoriasis, history of any clinically significant (as determined by the
             Investigator) cardiac (clinically advanced cardiovascular disease including; Stent,
             past history of MI, thrombotic event or arterial calcification), endocrinologic,
             pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease,
             or other major uncontrolled disease.

             2. Any condition, including the presence of laboratory abnormalities, which would
             place the subject at unacceptable risk if he/she were to participate in the study.

             3. Any condition, including other inflammatory diseases or dermatologic conditions
             that confound the ability to interpret data from the study.

             4. Prior history of suicide attempt at any time in the subject's life time prior to
             screening or randomization, or major psychiatric illness requiring hospitalization
             within the last 3 years.

             5. Pregnant or breast feeding.

             6. Have failed more than 3 systemic agents for treatment of psoriasis.

             7. History of allergy to any component of Apremilast.

             8. Hepatitis B surface antigen positive at Screening.

             9. Anti-hepatitis C antibody positive at Screening.

             10. Had a serious infection (including, but not limited to, hepatitis, pneumonia,
             sepsis, cellulitis, meningitis or pyelonephritis) or have been hospitalized for an
             infection. Subject must be cured of infection &gt; 4 weeks before Screening.

             11. Have a history of, or ongoing, chronic or recurrent infectious disease, including,
             but not limited to, chronic renal infection, chronic chest infection (e.g.,
             bronchiectasis), sinusitis, recurrent urinary tract infection (e.g., recurrent
             pyelonephritis, chronic nonremitting cystitis), an open, draining, or infected skin
             wound or ulcer.

             12. Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.

             13. History of positive human immunodeficiency virus (HIV), or have congenital or
             acquired immunodeficiency (e.g., common variable immunodeficiency disease).

             14. Active substance abuse or a history of substance abuse within 6 months prior to
             Screening.

             15. Bacterial infections requiring treatment with oral or injectable antibiotics, or
             significant viral or fungal infections, within 4 weeks of Screening. Any treatment and
             cure for such infections must have been completed at least 4 weeks prior to Screening.

             16. Malignancy or history of malignancy, except for:

               1. treated [i.e., cured] basal cell or squamous cell in situ skin carcinomas;

               2. treated [i.e., cured] cervical intraepithelial neoplasia [CIN] or carcinoma in
                  situ of the cervix with no evidence of recurrence within the previous 5 years.

                  17. Topical therapy within 2 weeks of study entry (including, but not limited to,
                  topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus,
                  pimecrolimus, or anthralin/dithranol). Exceptions: low-potency corticosteroids to
                  cyclosporine, corticosteroids, methotrexate, retinoids, mycophenolate,
                  thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, fumaric acid
                  esters) will be allowed as background therapy and restricted to treatment of the
                  face, axillae, and groin in accordance with the manufacturers' suggested usage
                  during the course of the study (this restricted usage should be documented).
                  Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or
                  salicylic acid scalp preparations on scalp lesions. An unmedicated skin
                  moisturizer (eg, Eucerin®) will be also permitted for body lesions only. Subjects
                  should not use these topical treatments within 24 hours prior to the clinic
                  visit.

                  18. Systemic therapy for psoriasis within 4 weeks prior to study entry
                  (including, but not limited to, cyclosporine, corticosteroids, methotrexate,
                  retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine,
                  azathioprine, and fumaric acid esters).

                  19. Use of phototherapy within 4 weeks prior to study entry.

                  20. Use of any investigational drug within 4 weeks prior to study entry, or 5
                  pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).

                  21. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV)
                  light sources.

                  22. Prior treatment with Apremilast

                  23. Inability to wash out from any topical treatment(s) (two weeks prior to
                  entering the study) or all systemic therapies, including orals and biologics
                  (e.g., TNF inhibitors IL-17 inhibitors, IL-12/23 inhibitors, 4 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erich M Zirzow, BS</last_name>
    <phone>216-844-7164</phone>
    <email>erich.zirzow@uhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Consolo, BS</last_name>
    <phone>216-844-7834</phone>
    <email>mary.consolo@uhhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Sanders, RN, MBA</last_name>
      <phone>216-844-7394</phone>
      <email>kim.sanders@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Neil J Korman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Cooper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas McCormick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008;26(2):121-9. Review.</citation>
    <PMID>18198932</PMID>
  </reference>
  <reference>
    <citation>Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat. 2005 Feb;16(1):37-42.</citation>
    <PMID>15897166</PMID>
  </reference>
  <reference>
    <citation>Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008 Nov;59(5):772-80. doi: 10.1016/j.jaad.2008.06.043.</citation>
    <PMID>19119095</PMID>
  </reference>
  <reference>
    <citation>Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Clinical and economic burden of psoriasis. Manag Care Interface. 2006 Apr;19(4):20-6. Review.</citation>
    <PMID>16689023</PMID>
  </reference>
  <reference>
    <citation>Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):157-63. doi: 10.1111/j.1468-3083.2010.03730.x. Epub 2010 Jun 17.</citation>
    <PMID>20561129</PMID>
  </reference>
  <reference>
    <citation>Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785-96. doi: 10.1038/jid.2010.103. Epub 2010 May 6. Review. Erratum in: J Invest Dermatol. 2010 Oct;130(10):2517. Jörg, Prinz C [corrected to Prinz, Jörg C].</citation>
    <PMID>20445552</PMID>
  </reference>
  <reference>
    <citation>Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010 Mar;29(1):10-5. doi: 10.1016/j.sder.2010.01.002. Review.</citation>
    <PMID>20430302</PMID>
  </reference>
  <reference>
    <citation>Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006 Oct;126(10):2194-201. Epub 2006 Jun 1.</citation>
    <PMID>16741509</PMID>
  </reference>
  <reference>
    <citation>Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 Apr;31(8):1000-6. doi: 10.1093/eurheartj/ehp567. Epub 2009 Dec 27.</citation>
    <PMID>20037179</PMID>
  </reference>
  <reference>
    <citation>Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-92. Review.</citation>
    <PMID>16343026</PMID>
  </reference>
  <reference>
    <citation>Au L, Meisch JP, Das LM, Binko AM, Boxer RS, Wen AM, Steinmetz NF, Lu KQ. Suppression of Hyperactive Immune Responses Protects against Nitrogen Mustard Injury. J Invest Dermatol. 2015 Dec;135(12):2971-2981. doi: 10.1038/jid.2015.322. Epub 2015 Aug 19.</citation>
    <PMID>26288355</PMID>
  </reference>
  <reference>
    <citation>Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today. 1996 Sep;17(9):424-8.</citation>
    <PMID>8854561</PMID>
  </reference>
  <reference>
    <citation>Martinez FO. The transcriptome of human monocyte subsets begins to emerge. J Biol. 2009;8(11):99. doi: 10.1186/jbiol206. Epub 2009 Dec 23. Review.</citation>
    <PMID>20067595</PMID>
  </reference>
  <reference>
    <citation>Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou X, Gabuzda D. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics. 2009 Aug 27;10:403. doi: 10.1186/1471-2164-10-403.</citation>
    <PMID>19712453</PMID>
  </reference>
  <reference>
    <citation>Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011 Aug 4;118(5):e16-31. doi: 10.1182/blood-2010-12-326355. Epub 2011 Jun 7.</citation>
    <PMID>21653326</PMID>
  </reference>
  <reference>
    <citation>Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, Heine GH. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011 Sep 22;118(12):e50-61. doi: 10.1182/blood-2011-01-326827. Epub 2011 Jul 29.</citation>
    <PMID>21803849</PMID>
  </reference>
  <reference>
    <citation>Zawada AM, Rogacev KS, Schirmer SH, Sester M, Böhm M, Fliser D, Heine GH. Monocyte heterogeneity in human cardiovascular disease. Immunobiology. 2012 Dec;217(12):1273-84. doi: 10.1016/j.imbio.2012.07.001. Epub 2012 Jul 25. Review.</citation>
    <PMID>22898391</PMID>
  </reference>
  <reference>
    <citation>Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010 Oct 21;116(16):e74-80. doi: 10.1182/blood-2010-02-258558. Epub 2010 Jul 13.</citation>
    <PMID>20628149</PMID>
  </reference>
  <reference>
    <citation>Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003 Jul;19(1):71-82.</citation>
    <PMID>12871640</PMID>
  </reference>
  <reference>
    <citation>Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92. doi: 10.1146/annurev.immunol.021908.132557. Review.</citation>
    <PMID>19132917</PMID>
  </reference>
  <reference>
    <citation>Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT, Lip GY. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost. 2011 May;9(5):1056-66. doi: 10.1111/j.1538-7836.2011.04244.x.</citation>
    <PMID>21342432</PMID>
  </reference>
  <reference>
    <citation>Gallego C, Golenbock D, Gomez MA, Saravia NG. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun. 2011 Jul;79(7):2871-9. doi: 10.1128/IAI.01388-10. Epub 2011 Apr 25.</citation>
    <PMID>21518783</PMID>
  </reference>
  <reference>
    <citation>Cao LY, Soler DC, Debanne SM, Grozdev I, Rodriguez ME, Feig RL, Carman TL, Gilkeson RC, Orringer CE, Kern EF, McCormick TS, Cooper KD, Korman NJ. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions. Am J Transl Res. 2013 Dec 1;6(1):16-27. eCollection 2013.</citation>
    <PMID>24349618</PMID>
  </reference>
  <reference>
    <citation>Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2012 Jul;10(7):1231-41. doi: 10.1111/j.1538-7836.2011.04603.x.</citation>
    <PMID>22212813</PMID>
  </reference>
  <reference>
    <citation>Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GY. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med. 2013 Mar;273(3):294-305. doi: 10.1111/joim.12011. Epub 2012 Dec 28.</citation>
    <PMID>23121518</PMID>
  </reference>
  <reference>
    <citation>Garcia-Rodriguez S, Arias-Santiago S, Perandrés-López R, Castellote L, Zumaquero E, Navarro P, Buendía-Eisman A, Ruiz JC, Orgaz-Molina J, Sancho J, M Zubiaur. Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013 Feb;27(2):242-50.</citation>
    <PMID>23457721</PMID>
  </reference>
  <reference>
    <citation>Benoit S, Toksoy A, Ahlmann M, Schmidt M, Sunderkötter C, Foell D, Pasparakis M, Roth J, Goebeler M. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol. 2006 Jul;155(1):62-6.</citation>
    <PMID>16792753</PMID>
  </reference>
  <reference>
    <citation>Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, Simon DI, Costa MA, Rodriguez B, Sieg SF, Lederman MM. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012 Nov 29;120(23):4599-608. doi: 10.1182/blood-2012-05-433946. Epub 2012 Oct 11.</citation>
    <PMID>23065151</PMID>
  </reference>
  <reference>
    <citation>Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther. 2010;12(1):R14. doi: 10.1186/ar2915. Epub 2010 Jan 26.</citation>
    <PMID>20102624</PMID>
  </reference>
  <reference>
    <citation>Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol. 2009 Mar;130(3):338-46. doi: 10.1016/j.clim.2008.09.011. Epub 2008 Oct 25.</citation>
    <PMID>18952503</PMID>
  </reference>
  <reference>
    <citation>Myśliwska J, Smardzewski M, Marek-Trzonkowska N, Myśliwiec M, Raczyńska K. Expansion of CD14+CD16+ monocytes producing TNF-α in complication-free diabetes type 1 juvenile onset patients. Cytokine. 2012 Oct;60(1):309-17. doi: 10.1016/j.cyto.2012.03.010. Epub 2012 Apr 7.</citation>
    <PMID>22484242</PMID>
  </reference>
  <reference>
    <citation>Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1210-6. doi: 10.1111/j.1572-0241.2007.01714.x. Epub 2008 Jan 2.</citation>
    <PMID>18177452</PMID>
  </reference>
  <reference>
    <citation>Skrzeczyñska J, Kobylarz K, Hartwich Z, Zembala M, Pryjma J. CD14+CD16+ monocytes in the course of sepsis in neonates and small children: monitoring and functional studies. Scand J Immunol. 2002 Jun;55(6):629-38.</citation>
    <PMID>12028567</PMID>
  </reference>
  <reference>
    <citation>Blumenstein M, Boekstegers P, Fraunberger P, Andreesen R, Ziegler-Heitbrock HW, Fingerle-Rowson G. Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemia. Shock. 1997 Jul;8(1):73-5.</citation>
    <PMID>9249916</PMID>
  </reference>
  <reference>
    <citation>Fingerle G, Pforte A, Passlick B, Blumenstein M, Ströbel M, Ziegler-Heitbrock HW. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood. 1993 Nov 15;82(10):3170-6.</citation>
    <PMID>7693040</PMID>
  </reference>
  <reference>
    <citation>Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, Lackner KJ, Iz M, Meyer J, Darius H, Rupprecht HJ. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004 Aug;92(2):419-24.</citation>
    <PMID>15269840</PMID>
  </reference>
  <reference>
    <citation>Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, Große-Dunker G, Heisel I, Hornof F, Jeken J, Rebling NM, Ulrich C, Scheller B, Böhm M, Fliser D, Heine GH. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012 Oct 16;60(16):1512-20. doi: 10.1016/j.jacc.2012.07.019. Epub 2012 Sep 19.</citation>
    <PMID>22999728</PMID>
  </reference>
  <reference>
    <citation>Wrigley BJ, Shantsila E, Tapp LD, Lip GY. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest. 2013 Feb;43(2):121-30. doi: 10.1111/eci.12023. Epub 2012 Dec 14.</citation>
    <PMID>23240665</PMID>
  </reference>
  <reference>
    <citation>Brunner PM, Koszik F, Reininger B, Kalb ML, Bauer W, Stingl G. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages. J Allergy Clin Immunol. 2013 Nov;132(5):1184-1193.e8. doi: 10.1016/j.jaci.2013.05.036. Epub 2013 Jul 26.</citation>
    <PMID>23890755</PMID>
  </reference>
  <reference>
    <citation>Golden JB, Groft SG, Squeri MV, Debanne SM, Ward NL, McCormick TS, Cooper KD. Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation. J Immunol. 2015 Sep 1;195(5):2006-18. doi: 10.4049/jimmunol.1402307. Epub 2015 Jul 29.</citation>
    <PMID>26223654</PMID>
  </reference>
  <reference>
    <citation>Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24.</citation>
    <PMID>20050849</PMID>
  </reference>
  <reference>
    <citation>Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May;138(5):657-63.</citation>
    <PMID>12020229</PMID>
  </reference>
  <reference>
    <citation>Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842-7.</citation>
    <PMID>11410193</PMID>
  </reference>
  <reference>
    <citation>Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007 Feb 8;356(6):580-92.</citation>
    <PMID>17287478</PMID>
  </reference>
  <reference>
    <citation>Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90. Review.</citation>
    <PMID>16979537</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Neil Korman</investigator_full_name>
    <investigator_title>Director, Clinical Trials Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

